



Kerstin Kampa-Schittenhelm

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Kerstin Kampa-Schittenhelm
Rorschacherstrasse 95
9007 St. Gallen

T +41 71 494 3574
Kerstin.Kampa-Schittenhelm@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Publications (14)

Bajrami Saipi M, Ruiba A, Schittenhelm M, Blumenstock G, Győrffy B, Fazio S, Hafner M, Ahrens A, Aldinger L, Aellig V, Kavelaars F, Nombela-Arrieta C, Fend F, Valk P, Driessen C, Kampa-Schittenhelm K. High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML). *Cell Death Dis* 2024; 15:869.

Schittenhelm M, Kaiser M, Győrffy B, Kampa-Schittenhelm K. Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML). *Cell Death Dis* 2024; 15:25.

Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. *Clin Case Rep* 2022; 10:e6296.

Tsintari V, Walter B, Fend F, Overkamp M, Rothermundt C, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS). *BMC cancer* 2022; 22:725.

Rieger I, Tsintari V, Overkamp M, Fend F, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. ASPP2 κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. *Front Mol Biosci* 2021; 8:727203.

Kampa-Schittenhelm K, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U, Illing B, Akmut F, Ganief T, Dreher S, Blumenstock G, Haeusser L, Bühring H, Tsintari V, Bonin M, Haverkamp T, Schittenhelm M. Epigenetic activation of O-linked β -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. *EBioMedicine* 2020; 54:102678.

Schittenhelm M, Lopez C, Fend F, Mau-Holzmann U, Illing B, Akmut F, Bajrami Saipi M, Federmann B, Tsintari V, Walter B, Kampa-Schittenhelm K. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. *EBioMedicine* 2019; 42:340-351.

Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBF β -MYH11 leukemia. *Oncotarget* 2018; 9:11876-11882.

Kampa-Schittenhelm K, Frey J, Haeusser L, Illing B, Pavlovsky A, Blumenstock G, Schittenhelm M. Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. *Oncotarget* 2017; 8:82897-82909.

Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. *BMC cancer* 2016; 16:25.

Schittenhelm M, Illing B, Akmut F, Rasp K, Blumenstock G, Döhner K, Lopez C, Kampa-Schittenhelm K. Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. *PloS one* 2013; 8:e80193.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. *Mol Cancer* 2013; 12:46.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Mol Cancer* 2013; 12:19.

Schittenhelm M, Kampa-Schittenhelm K, Yee K, Heinrich M. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. *Cell Cycle* 2009; 8:2621-30.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch